Ioana R. Preston
Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)

Dr. Ioana R. Preston

Intensive Care Medicine | Pulmonary Medicine
Lahey Clinic Inc
41 Mall Rd, 
Burlington, MA 
Accepting New Patients
Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Lahey Clinic Inc
41 Mall Rd, 
Burlington, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ioana Preston is an Intensive Care Medicine specialist and a Pulmonary Medicine provider in Burlington, Massachusetts. Dr. Preston is rated as an Advanced provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). Her top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Heart Failure with Preserved Ejection Fraction (HFpEF), Cerebral Hypoxia, and Lung Transplant. Dr. Preston is currently accepting new patients.

Her clinical research consists of co-authoring 89 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 5 articles and participated in 2 clinical trials in the study of Heart Failure with Preserved Ejection Fraction (HFpEF).

Specialties
Intensive Care Medicine
Pulmonary Medicine
Licenses
Critical Care Medicine in RI
Hospital Affiliations
Winchester Hospital
Lahey Hospital & Medical Center, Burlington
Northeast Hospital Corporation
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

LAHEY CLINIC INC
41 Mall Rd, Burlington, MA 01805

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
Enrollment Status: Terminated
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
A Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004
A Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004
Enrollment Status: Terminated
Publish Date: February 22, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

86 Total Publications

Pericardial effusion in sotatercept phase 3 trials: insights from STELLAR and ZENITH.
Pericardial effusion in sotatercept phase 3 trials: insights from STELLAR and ZENITH.
Journal: The European respiratory journal
Published: April 10, 2025
Similar Doctors
Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Elizabeth S. Klings
Pulmonary Medicine | Intensive Care Medicine
Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Elizabeth S. Klings
Pulmonary Medicine | Intensive Care Medicine

Evans Medical Foundation Inc

88 E Newton St, 
Boston, MA 
 (12.3 miles away)
617-414-5405
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Elizabeth Klings is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Boston, Massachusetts. Dr. Klings is rated as a Distinguished provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). Her top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Heart Failure with Preserved Ejection Fraction (HFpEF), and Venous Thromboembolism (VTE). Dr. Klings is currently accepting new patients.

Aaron B. Waxman
Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Aaron B. Waxman
Pulmonary Medicine | Intensive Care Medicine
Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Aaron B. Waxman
Pulmonary Medicine | Intensive Care Medicine

Brigham And Womens Physicians Organization Inc

75 Francis St, 
Boston, MA 
 (11.4 miles away)
617-732-5500
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Aaron Waxman is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Boston, Massachusetts. Dr. Waxman is rated as a Distinguished provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Interstitial Lung Disease, Lung Transplant, and Thrombectomy. Dr. Waxman is currently accepting new patients.

Payam Aghassi
Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Payam Aghassi
Pulmonary Medicine | Allergy and Immunology | Intensive Care Medicine
Advanced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Dr. Payam Aghassi
Pulmonary Medicine | Allergy and Immunology | Intensive Care Medicine

Mass Lung And Allergy PC

100 Hospital Rd, Suite 2a, 
Leominster, MA 
 (28.6 miles away)
978-466-2692
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Payam Aghassi is a Pulmonary Medicine specialist and an Allergy and Immunologist in Leominster, Massachusetts. Dr. Aghassi is rated as a Distinguished provider by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Obstructive Sleep Apnea, Gastrostomy, and Endoscopy. Dr. Aghassi is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Preston's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile